Medetomidine ('Rhino Tranq') Detected in U.S. Fentanyl Supply: What Families Need to Know

A new adulterant is spreading through the U.S. illegal drug supply — and most people using drugs have no idea they are taking it. In April 2026, the Centers for Disease Control and Prevention (CDC) issued a national Health Advisory about medetomidine, a powerful veterinary sedative increasingly found mixed with fentanyl. On May 12, the Drug Enforcement Administration (DEA) followed with a Public Safety Advisory warning that these hidden mixtures are placing users at higher risk of fatal poisoning.

This article explains what medetomidine is, why it matters for overdose response, and what families and people who use drugs can do to stay safer.

What Is Medetomidine?

Medetomidine — sometimes called "rhino tranq," "mede," or "dex" on the street — is an alpha-2 adrenergic agonist sedative approved only for veterinary use, primarily in dogs. It is not approved for human use by the FDA.

Its dextro-isomer, dexmedetomidine, is used in hospitals for procedural sedation in humans. But the medetomidine appearing in the illegal drug supply is different: laboratory testing has found racemic mixtures of both isomers, without the preservatives found in pharmaceutical or veterinary products. This strongly suggests the drug is being synthesized in clandestine labs, not diverted from legitimate veterinary supplies.

Medetomidine is chemically related to xylazine ("tranq"), the veterinary tranquilizer that has contaminated fentanyl supplies since 2021. However, medetomidine is more potent and longer-acting than both xylazine and clonidine, making it particularly dangerous when mixed with opioids.

How Widespread Is It?

The geographic spread of medetomidine is expanding rapidly:

2021: First detected in the U.S. illegal drug supply
2023–2024: Reports to the National Forensic Laboratory Information System (NFLIS) jumped 950% — from 247 to 2,616
2025: Another 215% increase to 8,233 reports

As of early 2026, medetomidine has been detected in drug samples and biological specimens from people who use illegal opioids in at least 18 states and the District of Columbia. The highest concentrations are in the Northeast (52%) and Midwest (31%), with growing presence in the South (17%) and West.

Data from CDC's Overdose Data to Action (OD2A) program found that from July to December 2025, medetomidine was detected in nearly 35% of opioid-positive samples across 20 sentinel surveillance sites. At eight of those sites, more than half of all opioid samples contained medetomidine. Wastewater testing in 14 states detected medetomidine every week between October 2025 and January 2026.

Critically, 98% of drug samples testing positive for medetomidine also contained fentanyl. The mixtures are typically sold as fentanyl or counterfeit pills, meaning users are often unaware they are consuming medetomidine.

Clinical Effects and Why It Complicates Overdoses

Medetomidine causes effects consistent with other alpha-2 agonists:

Profound sedation — deep, unresponsive sleep-like states
Severe bradycardia — heart rates as low as 32 beats per minute
Hypotension — dangerously low blood pressure
Respiratory depression — slowed or stopped breathing

Because medetomidine is not an opioid, naloxone (Narcan) — the standard overdose reversal medication — does not reverse its sedative or cardiovascular effects. This is the same challenge clinicians face with xylazine-adulterated fentanyl.

However, because fentanyl is involved in the vast majority of medetomidine-related overdoses, naloxone should still be administered immediately to restore breathing. The problem is that even after naloxone reverses the opioid component, the person may remain deeply sedated due to medetomidine, with dangerously slow heart rate and low blood pressure.

A New Danger: Severe Withdrawal Syndrome

Perhaps the most alarming finding in the CDC advisory is the risk of severe withdrawal syndrome following medetomidine exposure. Because medetomidine is more potent and longer-acting than clonidine, stopping it after regular use can trigger a withdrawal syndrome similar to but more intense than clonidine withdrawal.

Symptoms include:

Severe hypertension (dangerously high blood pressure)
Anxiety and agitation
Nausea and vomiting
Fluctuating alertness
Organ stress requiring emergency or intensive care

This withdrawal can occur after naloxone administration during an overdose, because naloxone removes the opioid effect but leaves the person in acute medetomidine withdrawal. The CDC specifically warns that this syndrome "can cause organ damage and often requires emergency or intensive care."

What This Means for Overdose Response

For Bystanders and Family Members

Call 911 immediately — Medetomidine overdoses require emergency medical care beyond what naloxone alone can provide.
Give naloxone anyway — Because fentanyl is almost always present, naloxone can restore breathing. But know that the person may not wake up fully.
Start rescue breathing — If the person is not breathing normally after naloxone, perform rescue breathing. The airway may need support longer than in a typical opioid overdose.
Place in recovery position — Deep sedation increases aspiration risk. Turn the person on their side.
Do not leave them alone — Medetomidine's effects can last longer than fentanyl's. Stay until emergency responders arrive.

For People Who Use Drugs

Never use alone — Have someone with you who can call for help and administer naloxone.
Test your supply — Drug test strips for fentanyl, xylazine, and medetomidine are increasingly available through harm reduction programs. However, no test strip is 100% reliable, and a negative result does not guarantee safety.
Start low, go slow — If using a new supply, take a smaller amount than usual and wait to feel effects before taking more.
Carry multiple doses of naloxone — Because medetomidine complicates overdose reversal, multiple naloxone doses may be needed. Carry at least two doses.

What Clinicians Should Know

The CDC advises clinicians to:

Consider medetomidine in suspected opioid overdoses with prolonged sedation unresponsive to naloxone
Consult a toxicologist or poison control at 1-800-222-1222 for guidance on managing alpha-2 agonist toxicity
Monitor for withdrawal in patients who survive overdose — severe hypertension and autonomic instability may develop hours after the acute event
Report unusual cases to the local health department

Emergency departments should be prepared for patients who remain sedated despite naloxone administration, and for the possibility of severe withdrawal syndromes requiring ICU-level care.

Harm Reduction Resources

Naloxone access:

Many states allow naloxone to be obtained without a prescription at pharmacies
Harm reduction organizations and health departments often provide free naloxone and training
Next Distro (nextdistro.org) mails naloxone to many states

Drug checking:

Some syringe service programs and harm reduction organizations offer fentanyl and xylazine test strips
Medetomidine test strips are becoming available in some jurisdictions
Check local harm reduction programs for availability

Never Use Alone hotline:

Call 1-877-696-1996 — a volunteer stays on the line while you use; if you stop responding, they call emergency services to your location

The Bottom Line

Medetomidine represents the next evolution in an already deadly drug supply. Its combination with fentanyl creates a toxic mixture where standard overdose reversal is incomplete, and where survival can be followed by severe, medically dangerous withdrawal.

The CDC and DEA advisories are not cause for panic — they are calls for preparedness. For families, this means ensuring naloxone is in the home and knowing how to use it. For people who use drugs, this means never using alone, testing supplies when possible, and understanding that the drug supply is more unpredictable than ever.

If you or someone you love is struggling with substance use, help is available. The SAMHSA National Helpline at 1-800-662-4357 provides free, confidential, 24/7 treatment referral and information. You can also visit findtreatment.gov to locate providers in your area.

Dr. Rachel Bennett is a board-certified addiction medicine physician with fifteen years of experience treating substance use disorders. She practices in the Pacific Northwest and writes about evidence-based treatment, medication-assisted recovery, and emerging drug safety threats.